Less than a month after securing CE marking for the Mallya smart sensor cap for injection pens, Biocorp SA, of Issoire, France, is in exclusive negotiations with Paris-based Sanofi SA, to deploy the device on Sanofi's integrated diabetes care platform. Final terms of the arrangement are still being hammered out, but it is expected to include an initial payment of €4 million (US$4.5 million) to Biocorp to advance product development and related activities.